Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18304932 | 0.84 | OPRL1 (0.44) | OPRL1POLBCCR3ALDH1A1CYP2D6 | |
| SCHEMBL6924615 | 0.82 | OPRL1 (0.57) | OPRL1POLBCCR3ALDH1A1CYP2D6 | |
| SCHEMBL17879605 | 0.79 | ALDH1A1 (0.33) | OPRL1POLBALDH1A1CYP2D6KMT2A | |
| SCHEMBL1266987 | 0.77 | OPRL1 (0.58) | OPRL1POLBCCR3ALDH1A1CYP2D6 | |
| SCHEMBL2883677 | 0.76 | OPRL1 (0.66) | OPRL1POLBCCR3ALDH1A1CYP2D6 | |
| SCHEMBL19358319 | 0.76 | MEN1 (0.52) | OPRL1ALDH1A1CYP2D6KMT2A | |
| Hydrochloric Acid SCHEMBL11256637 | 0.75 | POLB (0.66) | OPRL1POLBCCR3ALDH1A1CYP2D6 | |
| SCHEMBL6967833 | 0.75 | OPRL1 (0.56) | OPRL1POLBCCR3ALDH1A1CYP2D6 | |
| SCHEMBL10916463 | 0.74 | OPRL1 (0.70) | OPRL1POLBCCR3ALDH1A1CYP2D6 | |
| SCHEMBL6649554 | 0.72 | OPRL1 (0.56) | OPRL1POLBCCR3CYP2D6CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044323-A1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | SUZHOU ZELGEN BIOPHARMACEUTICALS CO LTD (CN) | 2018-02-15 | — | — | US | disclosed |
| US-9809572-B2 | Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2017-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044323-A1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | DCK, DPYD, BRAF | OPRL1 4403/4885POLB 470/4885CCR3 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.